Explore the words cloud of the EBOMAN project. It provides you a very rough idea of what is the project "EBOMAN" about.
The following table provides information about the project.
|Coordinator Country||Germany [DE]|
|Total cost||40˙188˙229 €|
|EC max contribution||1˙023˙325 € (3%)|
1. H2020-EU.188.8.131.52. (Other)
|Duration (year-month-day)||from 2014-12-01 to 2017-11-30|
Take a look of project's partnership.
|1||VIBALOGICS GMBH||DE (CUXHAVEN)||coordinator||1˙023˙325.00|
|2||BAVARIAN NORDIC AS||DK (KVISTGARD)||participant||0.00|
|3||JANSSEN VACCINES & PREVENTION BV||NL (LEIDEN)||participant||0.00|
This topic response (Topic 2: Manufacturing Capability) forms part of an integrated proposal to address the urgent unmet needs of accelerating the development of an Ebola vaccine. To help facilitate this main goal additional activities will be performed; the generation of sufficient vaccine and the capacity increase for generating more vaccine by means of process scale up and improvements.
The main objectives of this proposal are to manufacture sufficient supplies (and overages) for the clinical studies described in topic 1 and to prepare for a rapid access to large quantities of Ad26.ZEBOV (prime) and MVA-BN®-Filo (boost) vaccine in case of further escalation of the Ebola outbreak (The clinical development may change requiring an alternative vaccine combination; vaccination strategy. Any changes will be subsequently reflected in the manufacturing of clinical supplies). In conjunction with topic 3 (Transport and Rapid Access Ebola Vaccine) we should be able to respond quickly to future emergency needs of the vaccine.
The program therefore covers immediate manufacturing of clinical material and creation of additional capacity (by scale up, process improvements) and product understanding (BSL classification downgrading, process and product characterisation) to cope with increased need for the vaccine. The program includes:
Manufacturing, release and supply of Ad26.ZEBOV and MVA-BN®-Filo vaccine candidate for clinical studies (outcome: released clinical material)
Process Development activities required to ensure scale up of Ad26.ZEBOV manufacturing to 50L and fully define the 300L scale MVA BN®-Filo production.
Execute process development activities to ensure scale up of Ad26.ZEBOV and MVA-BN®-Filo to support potential manufacturing of up to 4M doses
Process Development and further scale up to support potential manufacturing of 10-20M doses
Generate material for further stability investigations towards late phase
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOMAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EBOMAN" are provided by the European Opendata Portal: CORDIS opendata.
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854Read More
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842Read More
Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890Read More